Pure Biologics S.A. (WSE:PUR)

Poland flag Poland · Delayed Price · Currency is PLN
3.046
-0.742 (-19.59%)
Mar 27, 2026, 5:02 PM CET
Market Cap46.38M -8.1%
Revenue (ttm)n/a
Net Income-17.93M
EPS-4.52
Shares Out12.24M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,274,561
Average Volume781,111
Open3.700
Previous Close3.788
Day's Range2.998 - 3.920
52-Week Range1.353 - 13.340
Beta0.60
RSI72.97
Earnings DateApr 30, 2026

About Pure Biologics

Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFβ1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the αVβ8 integrin. The company was founded in 2010 and is based in Wrocław, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 6
Stock Exchange Warsaw Stock Exchange
Ticker Symbol PUR
Full Company Profile

Financial Performance

Financial Statements